Eagle Pharmaceuticals,Inc. (TLV:TEVA) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial
Condition.

Item 7.01 Regulation FD
Disclosure.

On January11, 2017, Eagle Pharmaceuticals,Inc., or the Company,
will present the attached discussion of the Companys business
model, products and product candidates at the 35th Annual J.P.
Morgan Healthcare Conference in San Francisco, California, being
held January9 13, 2017.

A copy of the above referenced presentation is furnished as
Exhibit99.1 to this Current Report on Form8-K. The information
furnished to Item 7.01 of this current report, including
Exhibit99.1, shall not be deemed to be filed for the purposes of
Section18 of the Securities Exchange Act of 1934, as amended. As
such, this information shall not be incorporated by reference
into any of the Companys reports or other filings made with the
Securities and Exchange Commission. The furnishing of the
information in this current report is not intended to, and does
not, constitute a determination or admission by the Company that
the information in this current report is material or complete,
or that investors should consider this information before making
an investment decision with respect to any security of the
Company.

Forward-Looking Statements

This report includes forward-looking statements within the
meaning of Section27A of the Securities Act of 1933, as amended,
and Section21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical fact
are forward-looking statements for purposes of this Current
Report on Form8-K, including statements concerning any
projections of cash and cash equivalents, expenses, revenue,
milestone payments, royalties, sales, tax assets or other
financial items, and any statements of assumptions underlying any
of the foregoing. In some cases, forward-looking statements can
be identified by the use of terminology such as may, will,
expects, plans, anticipates, estimates, or the negative thereof
or other comparable terminology. Although we believe that the
expectations reflected in the forward-looking statements
contained herein are reasonable, such expectations or any of the
forward-looking statements may prove to be incorrect and actual
results could differ materially from those projected or assumed
in the forward-looking statements. Our future financial condition
and results of operations, as well as any forward-looking
statements, are subject to inherent risks and uncertainties,
including, but not limited to, the risk factors set forth in
PartII,Item 1A Risk Factors in our Quarterly Report on Form10-Q
for the quarter ended September30, 2016 and for the reasons
described elsewhere therein. All forward-looking statements and
reasons why results may differ included in this report are made
as of the date hereof and the Company does not intend to update
any forward-looking statements except as required by law or
applicable regulations.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits

About Eagle Pharmaceuticals, Inc. (TLV:TEVA)

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson’s disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women’s health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Eagle Pharmaceuticals, Inc. (TLV:TEVA) Recent Trading Information

Eagle Pharmaceuticals, Inc. (TLV:TEVA) closed its last trading session up +250.00 at 13,580.00 with 629,848 shares trading hands.